Invicta Diagnostic Ltd (INVICTA) — shareholding pattern, promoter holding, financials and share price
About Invicta Diagnostic Ltd (INVICTA)
Invicta Diagnostic Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as INVICTA and on the BSE under scrip code 93514. Its ISIN is INE0XJ501010.
Incorporated in January 2021, Invicta Diagnostic Limited offers radiology and pathology solutions [1]
Listed peers in Healthcare Service Provider: Nephro Care India Ltd, Aspira Pathlab & Diagnostics Ltd, Choksi Laboratories Ltd, Modern Diagnostic & Research Centre Ltd, Bandaram Pharma Packtech Ltd, N G Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹69 a share on 10 Jul 2026, Invicta Diagnostic Ltd (INVICTA) was valued at a price-to-earnings ratio of 17.69x against an industry P/E of 61.73x and a price-to-book of 1.74x on a book value of ₹39.71 per share. Solomo computes return on equity of 9.83% and return on capital employed of 13.44% from filed results.
- P/E
- 17.69x
- Industry P/E
- 61.73x
- P/B
- 1.74x
- EPS (TTM)
- ₹3.9
- Book value / share
- ₹39.71
- ROE
- 9.83%
- ROCE
- 13.44%
- ROA
- 8.08%
- Debt / equity
- 0.07x
- Dividend yield
- 0%
- EBITDA margin
- 32.29%
- 52-week range
- ₹58.1 – ₹105
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Invicta Diagnostic Ltd (INVICTA) reported revenue of ₹32.35 crore, net profit of ₹4.88 crore and earnings per share of ₹3.91. That compares with revenue of ₹30.1 crore and net profit of ₹4.69 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹15.41 crore and net profit ₹0.79 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 7.46 | 7.99 | 30.1 | 32.35 |
| Net profit (₹ cr) | 1.76 | 2.69 | 4.69 | 4.88 |
| EPS (₹) | - | 204.56 | 5.57 | 3.91 |
| Measure | 1Y |
|---|---|
| Sales growth | 276.72% |
| Profit growth | 74.35% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 66.7% of Invicta Diagnostic Ltd (INVICTA). Market capitalisation was ₹87 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Mar 2026: SHINE STAR BUILD CAP PVT LTD 3.22%, PINE OAK GLOBAL FUND 2.72%, NIHAR AMIT DAVE 2.38%, RGSL INVESTMENT FUND - RGSL INVESTMENT LVF 1 1.64%, AVORA SME FUND 1 1.16%, INVESTI GLOBAL OPPORTUNITY FUND PCC - CELL 1 1.02%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 66.7% | - | - | - | - |